Home Biomarkers CK-MB

CK-MB

Cardiac profile Biomarker

Sample Needed

Collection Type: Blood

Body System

Related System: Cardiac profile

Overview

CK‑MB is the creatine kinase isoenzyme that is relatively specific to heart muscle (myocardium). The CK‑MB test measures the concentration or activity of this isoenzyme in blood and is used to detect myocardial cell injury or necrosis that releases intracellular enzymes into the circulation. It is commonly used when acute coronary syndromes (chest pain, pressure, shortness of breath, diaphoresis, syncope) or other cardiac conditions (myocarditis, pericarditis, post‑cardiac surgery, blunt chest trauma) are suspected. Results can vary with age, sex and muscle mass (men and very muscular individuals tend to have higher baseline total CK), renal function (reduced clearance can raise levels), recent surgery/trauma, and timing relative to symptom onset.

People also test for

Test Preparation

No special preparation is required

Why Do I Need This Test

Profile: included in the Cardiac profile (cardiac enzyme panel).
Symptoms: chest pain, sudden shortness of breath, unexplained syncope, or suspected myocardial injury.
Diagnoses/monitoring: acute myocardial infarction (MI), reinfarction, myocarditis, monitoring after cardiac procedures.
Reasons for abnormal levels: myocardial necrosis, skeletal muscle injury, recent surgery/trauma, renal impairment, electrical cardioversion.
Biological meaning: elevated CK‑MB indicates myocardial cell membrane damage and enzyme release into blood.
Behaviors/lifestyle: strenuous exercise, intramuscular injections or muscle trauma can raise values.
Family history: early coronary artery disease or familial cardiomyopathies increases need for testing if symptomatic.

Run our symptom checker to see if this test is right for you

Symptom Checker

Understanding Test Results

Values <5 ng/mL (<5% of total CK) are considered within the normal range.
Mild elevations (≈5–10 ng/mL) may reflect minor cardiac injury, early MI, or noncardiac muscle injury and require correlation with symptoms, ECG and troponin.
Levels ≈10–25 ng/mL suggest probable myocardial injury and are commonly seen in acute MI; values >25 ng/mL are strongly suggestive of significant myocardial necrosis but thresholds vary by lab.
The CK‑MB index (CK‑MB/total CK ×100) >2.5 (or CK‑MB percentage >5–6%) supports a cardiac source.
CK‑MB typically rises 3–6 hours after chest pain onset, peaks at ~12–24 hours and returns to baseline by 48–72 hours a second rise after decline suggests reinfarction.
Interpret results with clinical findings and more sensitive markers (troponin); false positives occur with major skeletal muscle injury, recent surgery, renal failure or electrical therapy.

Normal Range

0-5 ng/mL OR <5% of total CK

FAQs

Q: What does high CK-MB mean?

A: High CK‑MB indicates increased levels of the CK‑MB isoenzyme, which commonly reflects heart muscle injury for example acute myocardial infarction, myocarditis, or after cardiac procedures. Mild rises can occur with skeletal muscle damage. CK‑MB is interpreted alongside symptoms, ECG changes and cardiac troponin tests to confirm diagnosis and guide further evaluation and treatment.

Q: What is the CPK MB test for?

A: The CPK‑MB (CK‑MB) blood test measures the heart-related isoenzyme of creatine kinase to detect and quantify heart muscle injury. It helps diagnose acute myocardial infarction, estimate damage extent, and monitor response or reinfarction after treatment. CK‑MB levels typically rise within 3–6 hours of injury, peak at 12–24 hours, and return toward baseline within 48–72 hours.

Q: Is CK-MB a cardiac marker?

A: Yes CK‑MB (creatine kinase‑MB) is an isoenzyme concentrated in heart muscle and has been used as a cardiac marker for myocardial infarction. It typically rises 3–6 hours after chest pain, peaks around 24 hours, and normalizes by 48–72 hours. Troponin has greater sensitivity and specificity and largely replaced CK‑MB, though CK‑MB can help detect reinfarction.

Q: Why is troponin better than CK-MB?

A: Troponin is superior because it’s much more cardiac‑specific and sensitive, detecting even small myocardial injury with high‑sensitivity assays. It rises early and stays elevated for days, broadening the diagnostic window and offering stronger prognostic information. CK‑MB is less specific and less sensitive; its shorter elevation can sometimes aid reinfarction detection, but troponin provides more reliable diagnosis and risk stratification.

Q: Is CK-MB a tumor marker?

A: CK‑MB is not a tumor marker. It’s a cardiac isoenzyme used to detect myocardial injury and acute myocardial infarction; elevations reflect heart muscle damage rather than malignancy. While some cancers can cause nonspecific rises in total creatine kinase, CK‑MB is not used to screen, diagnose, or monitor cancer—tumor markers such as CEA, CA‑125, PSA, and AFP serve those roles.

Q: How to treat high CK-MB?

A: High CK‑MB indicates possible heart muscle injury; treatment targets the underlying cause. For suspected myocardial infarction, urgent care includes antiplatelet therapy (aspirin), anticoagulation, nitroglycerin, beta‑blockers when appropriate, oxygen if hypoxic, pain control, and rapid reperfusion (primary PCI or thrombolysis). Monitor ECG, enzymes and hemodynamics, treat arrhythmias, and seek immediate medical evaluation. Noncardiac causes need condition‑specific care.